Neumora Therapeutics Inc
neumoratx.comWhat Do They Do?
Develops investigational medicines for patients with brain and metabolic disorders, including depression, Alzheimer’s-related agitation and schizophrenia.
10-K for FY2025, filed Mar 30, 2026
How Do They Make Money?
No revenue reported yet.
10-K for FY2025, filed Mar 30, 2026
How Are They Changing?
- Net income
-
Sources
10-Q for Q2 FY2026, filed Aug 14, 2026
−$43.1MView ↗
- ▼ −18% (Loss)
- vs −$52.7M in Q2 FY2025
-
Aug 14, 2026
Names Joshua Pinto CEO and makes Paul Berns Executive Chair
Sources
8-K, filed Aug 14, 2026
On August 14, 2026, the Company announced that Paul L. Berns, the Company’s current Chief Executive Officer, will become the Company’s…View ↗
-
Jun 15, 2026
Discontinues navacaprant after Phase 3 studies miss key endpoints
The company also announced a workforce reduction of approximately 35%.
Sources
8-K, filed Jun 15, 2026
On June 15, 2026, the Company announced that the Phase 3 KOASTAL-2 and -3 studies of navacaprant for the treatment of major depressive…View ↗
Who Do They Compete With?
Competes with Axsome Therapeutics, Denali Therapeutics, Neurocrine Biosciences, Prothena, and Xenon Pharmaceuticals
10-K for FY2025, filed Mar 30, 2026Neumora is a clinical-stage biopharmaceutical company founded to confront the global brain disease crisis by taking a fundamentally…View ↗
Loading...
